1 |
TNFRSF13C
💬
| [5] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Human T-cell leukemia virus 1 infection, Primary immunodeficiency | Ianalumab
Ianalumab
💬
|
Ianalumab
| [7] 35 35, 46, 49, 53, 61, 63, 95 💬 |
2 |
IL2RG
💬
| [12] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Inflammatory bowel disease, Primary immunodeficiency | Aldesleukin
Aldesleukin
💬
|
Aldesleukin
| [6] 2 2, 35, 49, 65, 96, 97 💬 |
3 |
JAK3
💬
| [15] Chemokine signaling pathway Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency | Tofacitinib
Tofacitinib
💬
|
Tofacitinib
| [15] 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬 |
4 |
JAK3
💬
| [15] Chemokine signaling pathway Chemokine signaling pathway, PI3K-Akt signaling pathway, Necroptosis, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Hepatitis B, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Pathways in cancer, Viral carcinogenesis, Non-small cell lung cancer, Primary immunodeficiency | Peficitinib
Peficitinib
💬
|
Peficitinib
| [1] 46 46 💬 |
5 |
LCK
💬
| [10] NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, Human T-cell leukemia virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | Dasatinib
Dasatinib
💬
|
Dasatinib
| [2] 51 51, 85 💬 |
6 |
LCK
💬
| [10] NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, Human T-cell leukemia virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | Dasatinib
Dasatinib
💬
|
Dasatinib
| [2] 51 51, 85 💬 |
7 |
BTK
💬
| [7] NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | Ibrutinib
Ibrutinib
💬
|
Ibrutinib
| [3] 28 28, 60, 61 💬 |
8 |
BTK
💬
| [7] NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | Acalabrutinib
Acalabrutinib
💬
|
Acalabrutinib
| [2] 46 46, 61 💬 |
9 |
BTK
💬
| [7] NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | Zanubrutinib
Zanubrutinib
💬
|
Zanubrutinib
| [5] 13 13, 63, 222, 300, 331 💬 |
10 |
BTK
💬
| [7] NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | Fenebrutinib
Fenebrutinib
💬
|
Fenebrutinib
| [1] 13 13 💬 |
11 |
BTK
💬
| [7] NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | Branebrutinib
Branebrutinib
💬
|
Branebrutinib
| [3] 46 46, 49, 53 💬 |
12 |
BTK
💬
| [7] NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | Orelabrutinib
Orelabrutinib
💬
|
Orelabrutinib
| [4] 13 13, 49, 61, 63 💬 |
13 |
BTK
💬
| [7] NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | Remibrutinib
Remibrutinib
💬
|
Remibrutinib
| [2] 13 13, 53 💬 |
14 |
BTK
💬
| [7] NF-kappa B signaling pathway NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | Evobrutinib
Evobrutinib
💬
|
Evobrutinib
| [3] 13 13, 46, 49 💬 |
15 |
CD3D
💬
| [11] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | Visilizumab
Visilizumab
💬
|
Visilizumab
| [2] 96 96, 97 💬 |
16 |
CD3D
💬
| [11] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | Otelixizumab
Otelixizumab
💬
|
Otelixizumab
| [1] 46 46 💬 |
17 |
CD3E
💬
| [11] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | Visilizumab
Visilizumab
💬
|
Visilizumab
| [2] 96 96, 97 💬 |
18 |
CD3E
💬
| [11] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | Otelixizumab
Otelixizumab
💬
|
Otelixizumab
| [1] 46 46 💬 |
19 |
CD3E
💬
| [11] Hematopoietic cell lineage Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Chagas disease, Measles, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | Mosunetuzumab
Mosunetuzumab
💬
|
Mosunetuzumab
| [1] 49 49 💬 |
20 |
CD4
💬
| [14] Viral life cycle - HIV-1 Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Cytokine-cytokine receptor interaction, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | Zanolimumab
Zanolimumab
💬
|
Zanolimumab
| [1] 46 46 💬 |
21 |
CD19
💬
| [5] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Hematopoietic cell lineage, B cell receptor signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | Obexelimab
Obexelimab
💬
|
Obexelimab
| [1] 300 300 💬 |
22 |
CD19
💬
| [5] PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Hematopoietic cell lineage, B cell receptor signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency | Inebilizumab
Inebilizumab
💬
|
Inebilizumab
| [4] 11 11, 13, 51, 300 💬 |
23 |
CD40
💬
| [17] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Bleselumab
Bleselumab
💬
|
Bleselumab
| [1] 222 222 💬 |
24 |
CD40
💬
| [17] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Ravagalimab
Ravagalimab
💬
|
Ravagalimab
| [2] 53 53, 97 💬 |
25 |
CD40
💬
| [17] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Iscalimab
Iscalimab
💬
|
Iscalimab
| [2] 49 49, 53 💬 |
26 |
CD40LG
💬
| [14] Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, T cell receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Toralizumab
Toralizumab
💬
|
Toralizumab
| [1] 63 63 💬 |